[About the estimation of fetal risk by evalution of the serum -- amniotic liqour -- ratio of HPL during the pregnancy (author's transl)].
Radioimmunoassay of human placental lactogen (HPL) is a valuable diagnostic tool for the early recognition of placental dysfunction. But, the rather wide normal range hampers HPL estimations to be used as a good prognostic tool. However, the simultaneous determination of HPL in maternal serum and in amniotic fluid allows a better diagnosis of the fetal well-being. Results of amniotic fluid HPL levels are expressed as percent of maternal serum levels. In this pilot study it was shown that this ratio of maternal serum HPL level to amniotic fluid level is below 10% in normal pregnancies. The ratio is between 10 to 20% in subjects where fetal distress was recorded, and dystrophic babies were observed. The value is above 20% in cases where intrauterine fetal deaths were found. This good correlation of the HPL ratio in maternal serum and amniotic fluid with the outcome of pregnancy offers a new means of using HPL estimation as prognostic tool.
D000653:Amniotic Fluid / Q000032:analysis; D005260:Female; D005313:Fetal Death; D005315:Fetal Diseases / Q000175:diagnosis; D006801:Humans; D010928:Placental Lactogen / Q000032:analysis* / Q000097:blood; D011247:Pregnancy; D011379:Prognosis
D010928:Placental Lactogen
Zur Abschätzung des kindlichen Risikos durch Bestimmung des Serum-Fruchtwasser-Quotienten von HPL während der Schwangerschaft